Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
12.53M | 0.00 | 0.00 | 40.02M | 33.87M | Gross Profit |
6.29M | 0.00 | 0.00 | 8.87M | 8.83M | EBIT |
-7.56M | -19.85M | -3.15M | -3.22M | -9.00M | EBITDA |
-4.97M | -3.29M | -3.15M | 1.90M | -4.30M | Net Income Common Stockholders |
-6.25M | -7.81M | 10.99M | -16.89M | -8.50M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
7.18M | 5.00K | 61.00K | 705.00K | 379.00K | Total Assets |
82.44M | 18.49M | 46.76M | 15.16M | 24.35M | Total Debt |
13.07M | 707.00K | 7.67M | 6.64M | 6.63M | Net Debt |
5.89M | 702.00K | 7.61M | 5.94M | 6.25M | Total Liabilities |
57.63M | 21.80M | 44.45M | 23.84M | 21.98M | Stockholders Equity |
20.89M | -3.31M | 2.31M | -8.68M | 2.37M |
Cash Flow | Free Cash Flow | |||
1.78M | 1.46M | -3.06M | -7.02M | -1.45M | Operating Cash Flow |
1.78M | 1.46M | -3.06M | -5.29M | -617.00K | Investing Cash Flow |
5.85M | -155.00K | -1.51M | -1.72M | -834.00K | Financing Cash Flow |
6.09M | -1.44M | 3.98M | 7.37M | 1.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $4.49B | 12.22 | 5.40% | 3.71% | 4.17% | -11.97% | |
46 Neutral | $165.82M | ― | -41.79% | ― | ― | 87.49% | |
$92.26M | ― | ― | ― | ― | |||
54 Neutral | $88.10M | ― | -189.13% | ― | 89.27% | 26.30% | |
37 Underperform | $65.55M | ― | -19.87% | ― | ― | ― | |
$64.81M | 0.59 | ― | ― | ― | |||
52 Neutral | $54.70M | ― | -170.91% | ― | -70.08% | -330.51% |
At its 2024 Annual General Meeting, ALT5 Sigma Corporation’s shareholders approved all proposed resolutions, including the re-election of key board members and the approval of the 2024 Equity Incentive Plan. The company reported record transaction volumes for its fintech platforms, reflecting strong customer trust and growth. Strategic initiatives include the planned spin-off of healthcare assets into Alyea Therapeutics Corporation, which is set to acquire Soin Bioscience LLC to enhance its pain management pharmaceutical pipeline. This separation will allow ALT5 to focus on its fintech operations while Alyea concentrates on healthcare innovations.
More about ALT5 Sigma Corporation
ALT5 Sigma Corporation is a Nasdaq-listed fintech firm specializing in blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safekeeping of digital assets. It operates the ALT5 Pay and ALT5 Prime platforms, which facilitate cryptocurrency payments and digital asset trading. The company is also engaged in developing non-addictive pain management solutions through its subsidiary, Alyea Therapeutics Corporation.
YTD Price Performance: 528.57%
Average Trading Volume: 170,649
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $49.52M